[1] Wang et al. Multiparametric MRI for Bladder Cancer: Validation of VI-RADS for the Detection of Detrusor Muscle Invasion. Radiology 2019;291:668-674.
[2] Soukup et al. Prognostic performance and reproducibility of the 1973 and 2004/2016 World Health Organization grading classification systems in non-muscle-invasive bladder cancer: a European Association of Urology Non-muscle Invasive Bladder Cancer Guidelines Panel systematic review. Eur Urol 2017;72:801–13.
[3] Tritschler S et al. Staging of muscle-invasive bladder cancer: can computerized tomography help us to decide on local treatment? World J Urol 2012;30:827–31.
[4] Van der Pol CB al (2018) ACR appropriateness criteria® pretreatment staging of muscle-invasive bladder cancer. JACR 15:S150–S159.
[5] Kim B et al. Bladder tumor staging: comparison of contrast-enhanced CT, T1- and T2-
weighted MR imaging, dynamic gadolinium-enhanced imaging, and late gadolinium-enhanced imaging. Radiology 1994;193:239–45.
[6] Panebianco V et al. Multiparametric Magnetic Resonance Imaging for Bladder Cancer: Development of VI-RADS (Vesical Imaging-Reporting And Data System). Eur Urol. 2018;74(3):294-306.
[7] Johnson W et al The value of hyoscine butylbromide in pelvic MRI. Clin Radiol
2007;62:1087–93.
[8] Barentsz JO et al. The role of MR imaging in carcinoma of the urinary bladder. AJR Am J Roentgenol 1993;160:937–47.
[9] Panebianco V, et al. Improving staging in bladder cancer: the increasing role of multiparametric magnetic resonance imaging. Eur Urol Focus 2016;2:113–21.
[10] Narumi Y et al. Bladder tumors: staging with gadolinium-enhanced oblique MR imaging. Radiology 1993;187:145–50.
[11] Narumi Y, et al. Bladder wall morphology: in vitro MR imaging-histopathologic correlation. Radiology 1993;187:151–5.
[12] Zhou G, et al. Contrast-enhanced dynamic and diffusion-weighted MR imaging at 3.0T to assess aggressiveness of bladder cancer. Eur J Radiol 2014;83:2013–8.
[13] Panebianco V et al. An evaluation of morphological and functional multi-parametric MRI sequences in classifying non-muscle and muscle invasive bladder cancer. Eur Radiol 2017;27:3759–66.
[14] MaW, et al. Imaging appearance of granulomatous disease after intravesical Bacille Calmette-Guerin (BCG) treatment of bladder carcinoma. AJR 2009;192:1494–500.
[15] Wang HJ et al. Comparison of early submucosal enhancement and tumor stalk in staging bladder urothelial carcinoma. AJR 2016;207:797–803.
[16] Schrier BP et al Evaluation of chemotherapy with magnetic resonance imaging in patients with regionally metastatic or unresectable bladder cancer. Eur Urol 2006;49:698–703.
[17] Nguyen HT et al. Prediction of chemotherapeutic response in bladder cancer using K-means clustering of dynamic contrast-enhanced (DCE)-MRI pharmacokinetic parameters. JMRI 2015;41:1374–82.
[18] Pavone C. et al. Transurethral ultrasonography, CT scan, nuclear magnetic resonance (NMR) imaging and pathological control in staging and follow up of invasive bladder carcinoma.Volume 260, 1988, Pages 251-263.